Xpert® vanA

Home / Tests / HAI & Other Infectious Diseases

Xpert® vanA

Rapid VRE screening for active outbreak prevention and control in around 48 minutes

Test pack size(s)

10 Tests

GXVANA-10

Qty

Unit price

Subtotal

USD

$0.00

Collection devices

Collection Device (Pack of 50)

900-0370

Qty

Unit price

Subtotal

USD

$0.00

Total

$0.00

The Need

Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities¹
In healthcare settings, colonized patients and environmental contamination contribute to VRE spread¹
High-risk patients colonized with VRE have 24 times increased infection risk²
Infections caused by VRE are associated with high mortality³
VRE has an impact on patient length-of-stay, and in turn, hospitalization costs³

1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023

2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.

3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

The Xpert vanA test is a rapid and accurate method for detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonized and infected patients⁴

4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663

The Impact

Rapid PCR results facilitate more efficient infection control surveillance programs⁵

93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
High negative predictive value allows for better management of non-colonized patients
Decreased the number of contact patients thereby preventing VRE transmission
94% reduction in overall cost ($15,645 with culture vs $952*)

Compared to culture, faster time to result may support more effective patient management: more isolation and transmission risk days saved⁶:

141 saved isolation days and 292 saved transmission risk days

5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.

6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59

* 1€=1.09$, conversion rate December 15th 2023